Close
18/03/2014
The public-private partnership ESTEVE-UAB is bearing fruit
ESTEVE has announced the signing of two agreements that will enable it to progress the development of its gene therapeutic for the treatment of Sanfilippo A Syndrome and begin a phase I/II clinical trial in 2015. The agreements are with the North American biotechnology company REGENX Biosciences, LLC (REGENX) and with the French non for profit organization GÉNÉTHON.
 
Sanfilippo A is a rare and devastating neurodegenerative disease that affects approximately 1 in every 100.000 children that rarely survive past adolescence.

This gene therapy program is being developed in a public-private partnership between ESTEVE and the research team of Dr. Fàtima Bosch at the Center for Biotechnology and Gene Therapy of the Universitat Autònoma de Barcelona (UAB).

In this partnership, ESTEVE leads all activities associated with the management and protection of intellectual property, regulatory activities, the coordination and supervision of GMP manufacturing, the preclinical toxicology studies as well as all clinical development.
The CBATEG research team at the UAB brings to the partnership their scientific know-how and expertise in gene therapy including viral vector design and the development of preclinical disease models.

Press release

More news

19/12/2016 ​Foundation stone ceremony for Natura Bissé’s new world headquarters in Barcelona Synchrotron Park 15/12/2016 ​The Bioregion of Catalonia in Nature 07/12/2016 Digitus II Awarded By Barcelona Synchrotron Park As Best Business Idea Of The UAB University Research Park 29/11/2016 ​The European Commission awards the “Business & Biodiversity” label to Barcelona Synchrotron Park 21/11/2016 ​Barcelona 2nd Smart City in the World 15/11/2016 Barcelona Synchrotron Park Sponsors the PRUAB Ideas Generation Program
20 21 22 23 24 25 26 27 28 29 30